Abstract:
An antibody, which specifically recognizes adducts between pyrrole and cellular macromolecules. Such adducts are likely to occur in mammals suffering an incident of pyrrolizidine alkaloid poisoning. The antibody can be produced using a synthetic immunogen conjugated with a pyrrole as a hapten and it can be used, for example in an assay kit and/or by itself, as a novel means for detecting or diagnosing pyrrolizidine alkaloid poisoning both clinics and research laboratories.
Abstract:
An antibody, which specifically recognizes adducts between pyrrole and cellular macromolecules. Such adducts are likely to occur in mammals suffering an incident of pyrrolizidine alkaloid poisoning. The antibody can be produced using a synthetic immunogen conjugated with a pyrrole as a hapten and it can be used, for example in an assay kit and/or by itself, as a novel means for detecting or diagnosing pyrrolizidine alkaloid poisoning both clinics and research laboratories.
Abstract:
This invention relates to novel haloenol lactone compounds. These compounds have the following general structure: in which Ar is an aryl group and Y is a haloenol lactone moiety. The compounds of the invention are useful for the specific measurement of particular isoenzymes of glutathione S-transferase. Measurement of glutathione S-transferase isoenzymes has importance in diagnostic medicine. The compounds of the invention are also useful for treatment of drug resistance in cancer and for preventing herbicide resistance in plants.
Abstract:
Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.
Abstract:
Biologically stable inhibitors of soluble epoxide hydrolases are provided. The inhibitors can be used, for example, to selectively inhibit epoxide hydrolase in therapeutic applications such as treating inflammation, for use in affinity separations of the epoxide hydrolases, and in agricultural applications. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, or being a metabolite or degradation product thereof.
Abstract:
The invention provides methods of using dihydroxy unsaturated fatty acids as markers for identifying patients with a disorder associated with abnormal regulation of the cytochrome P450 metabolism or oxidation of unsaturated fatty acids. For example, linoleic acid diols, including leukotoxindiol, can be used as a diagnostic tool for identifying patients with pre-eclampsia, eclampsia, and pregnancy-induced hypertension.
Abstract:
This invention relates to novel haloenol lactone compounds. These compounds have the following general structure: ##STR1## in which Ar is an aryl group and Y is a haloenol lactone moiety. The compounds of the invention are useful for the specific measurement of particular isoenzymes of glutathione S-transferase. Measurement of glutathione S-transferase isoenzymes has importance in diagnostic medicine. The compounds of the invention are also useful for treatment of drug resistance in cancer and for preventing herbicide resistance in plants.
Abstract:
The present invention provides methods of treating inflammatory diseases mediated by poly-unsaturated lipid metabolites by inhibiting epoxide hydrolase, methods for assaying or screening the epoxide hydrolase inhibitors for inhibitory specificity and for toxicity, and novel biologically active tetrahydrofuran diols of arachidonic acid, including antibodies thereto.
Abstract:
Biologically stable inhibitors of soluble epoxide hydrolases are provided. The inhibitors can be used, for example, to selectively inhibit epoxide hydrolase in therapeutic applications such as treating inflammation, for use in affinity separations of the epoxide hydrolases, and in agricultural applications. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 ##STR1## wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R.sub.1 -R.sub.4 is hydrogen, R.sub.2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R.sub.4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R.sub.1 and R.sub.3 are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, or being a metabolite or degradation product thereof.
Abstract:
This invention relates to novel haloenol lactone compounds. These compounds have the following general structure: ##STR1## in which Ar is an aryl group and Y is a haloenol lactone moiety. The compounds of the invention are useful for the specific measurement of particular isoenzymes of glutathione S-transferase. Measurement of glutathione S-transferase isoenzymes has importance in diagnostic medicine. The compounds of the invention are also useful for treatment of drug resistance in cancer and for preventing herbicide resistance in plants.